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The classic pathway (CP) of complement is believed to significantly contribute to alloantibody-mediated transplant injury, and targeted complement inhibition is currently considered to be a promising approach for preventing rejection. Here, we investigated the mode of action and efficacy of the humanized anti-C1s monoclonal antibody TNT009 and its parental mouse variant, TNT003, in preclinical in vitro models of HLA antibody-triggered CP activation. In flow cytometric assays, we measured the attachment of C1 subcomponents and C4/C3 split products (C4b/d, C3b/d) to HLA antigen-coated flow beads or HLA-mismatched aortic endothelial cells and splenic lymphocytes. Anti-C1s antibodies profoundly inhibited C3 activation at concentrations >20 lg/mL, in both solid phase and cellular assays. While C4 activation was also prevented, this was not the case for C1 subcomponent attachment. Analysis of serum samples obtained from 68 sensitized transplant candidates revealed that the potency of inhibition was related to the extent of baseline CP activation. This study demonstrates that anti-C1s antibodies TNT009 and TNT003 are highly effective in blocking HLA antibody-triggered complement activation downstream of C1. Our results provide the foundation for clinical studies designed to investigate the potential of TNT009 in the treatment or prevention of complement-mediated tissue injury in sensitized transplant recipients.
Introduction
The classic pathway (CP) of complement plays an important role in many aspects of health and disease. Immunoglobulin binding to target antigens is a major trigger of the CP, which is critical in the defense against pathogens and the physiologic clearance of immune complexes, but may also cause tissue injury in a variety of disease states (1, 2) . The CP is recognized as being involved also in antibody-mediated rejection (AMR) of organ transplants (3, 4) . This type of rejection is an important cause of transplant injury, significantly contributing to inferior graft function and survival (5) . AMR represents a major therapeutic challenge (6, 7) , and a thorough understanding of its pathophysiology could provide guidance toward the development of new effective therapeutic approaches.
Targeting complement may represent a promising therapeutic strategy (3, 10) . The anti-C5 antibody eculizumab was recently shown to effectively prevent acute AMR in sensitized kidney transplant recipients (11) . However, eculizumab treatment failed to prevent chronic injury in crossmatch-positive patients (12) and only marginally improved kidney function in patients with chronic AMR (13) . These results may be explained in part by complement-independent pathways of antibody-mediated injury (14, 15) . Alternatively, inhibition at the level of C5 does not prevent the generation of important upstream inflammatory mediators such as the anaphylatoxin C3a that may significantly contribute to the rejection process (16) .
In contrast, a CP-specific therapeutic approach targeting the CP component C1 would interfere with the production of upstream inflammatory split products. This strategy has the added benefit of leaving the lectin and alternative pathways intact to mediate host defense. Recent studies have focused on C1 esterase inhibitor (C1-INH) (17) (18) (19) . Its mode of action, however, is not restricted to C1 inhibition and also includes effects on the lectin pathway, coagulation pathways, fibrinolytic and kinin-kallikrein systems (20) . Further, achieving therapeutically efficacious concentrations of C1-INH, an endogenous protein already at high concentrations in the circulation (>200 lg/mL), may prove to be challenging.
An alternative target of interest may be C1s, the serine protease within the C1 complex responsible for the cleavage of C4 and C2 and the formation of the CP C3 convertase. Recently, TNT003, a mouse mAb selectively targeting the C1 subcomponent C1s, was shown to effectively block antibody-mediated CP activation in experimental in vitro models of cold agglutinin-mediated hemolysis and HLA antibody-triggered complement activation (21, 22) . Now, a humanized variant of this antibody, TNT009, has been developed and is currently being tested in healthy volunteers and patients with autoimmune disease or AMR in a phase 1 trial (ClinicalTrials.gov Identifier: NCT02502903) (23).
In the study presented here, we sought to investigate the effect of TNT009 compared with its parental variant TNT003, on HLA antibody-triggered CP activation. To enable a detailed characterization of the sequential steps of CP activation, we applied a flow bead assay (24) (25) (26) (27) . The effect of anti-C1s mAbs on HLA antibody-triggered CP activation was also analyzed in cellular assays using HLA-mismatched donor lymphocytes and aortic endothelial cells (AECs).
Materials and Methods
Anti-C1s mAbs and isotype controls TNT009, a humanized anti-C1s mAb (IgG4 isotype, stock solution: 1 mg/ mL), and its parental mouse variant, TNT003 (IgG2a isotype, stock solution: 1 mg/mL), were obtained from True North Therapeutics, Inc. (South San Francisco, CA). Nonspecific human IgG4 (Abcam PLC, Cambridge, UK) or mouse IgG2a (Bio X Cell, West Lebanon, NH) served as the isotype controls. The targets of TNT009/TNT003 and other complement inhibitors used in this study are illustrated in Figure S1 .
Patients and sera
For in vitro CP activation, we selected a polyspecific alloserum obtained from a highly immunized dialysis patient showing 76% complementdependent cytotoxicity panel reactivity and, as assessed in single antigen flow bead (SAFB) assays, 99.8% and 97.6% virtual HLA class I IgG and C3b/d-fixing panel reactivity, respectively (Virtual PRA Calculator provided by the Eurotransplant Reference Laboratory). For select experiments, we used an alloserum containing C3b/d-fixing reactivity only against HLA-A2 (monospecific serum). In addition, we prescreened the sera of 308 kidney transplant candidates. Samples from 99 subjects showed significant IgG reactivity in HLA class I and/or II SAFB assays. Sixty-eight patients were selected according to significant levels of C3b/d fixation (mean fluorescence intensity [MFI] > 100) to at least one SAFB (45 patients had HLA class I and 54 had HLA class II SAFB reactivity).
Solid phase measurement of HLA reactivity
For detection of overall IgG type HLA reactivity, we applied LABScreen Mixed beads (One Lambda, Inc, Canoga Park, CA). Samples were analyzed using a Luminex 100 flow analyzer (Luminex Corporation, Austin, TX), and, using HLA fusion 3.0 software, results were reported as a normalized background ratio, whereby a positive ratio was set at >1.5.
For characterization of IgG single reactivity and alloantibody-triggered complement deposition, we used LABScreen Single Antigen assays (One Lambda Inc.), which consist of 97 (HLA class I) and 95 (HLA class II) individual SAFB populations coated with different HLA alleles. IgG binding was detected according to the manufacturer's instructions. In brief, beads were incubated for 30 min at 22°C with heat-inactivated undiluted alloserum followed by 30 min incubation with phycoerythrin (PE)-labeled anti-human IgG. A positive SAFB result was defined as an MFI >1000. Figure S1 . Beads were then washed and incubated for additional 30 min with biotin-labeled polyclonal rabbit antibody against human C1q (final concentration: 50 lg/mL; Assaypro, LLC, St. Charles, MO, USA), C1r (goat anti-human, affinity purified, 10 lg/mL; R&D Systems, Inc., Minneapolis, MN), C1s (sheep anti-human, 10 lg/mL; R&D Systems, Inc.), and biotin-labeled mouse mAbs against human C4d (10 lg/mL) or C3d (4 lg/mL; both antibodies were from Quidel, San Diego, CA) followed by 30 min incubation with PE-conjugated streptavidin (final concentration: 1 lg/mL; eBioscience, San Diego, CA) before measurement on a Luminex platform. For complement binding assays, individual MFI thresholds, which were lower than those commonly used for IgG detection, were defined on the basis of (1) reactivity detected on negative control beads and (2) the individual MFI ranges recorded for HLA antigen-coated beads incubated with serum samples obtained from sensitized patients. Assay results were considered positive if the detected raw MFI exceeded a value of 100 (C1r, C1s, C4d, and C3d) or 250 (C1q), respectively. MFI levels recorded for negative control beads were in all experiments <40 for C1r, C1s, and C3d, <100 for C4d, and <200 for C1q.
Cell-based detection of alloantibody-triggered complement deposition
Primary endothelial cells of three deceased blood group O donors were isolated from aorta via digestion with collagenase H (Sigma-Aldrich Corp.). Isolated cells were grown to confluency on gelatin-coated culture flasks in EGM-2-MV medium (Lonza, Basel, Switzerland) and selected by anti-CD31 coupled to magnetic beads between days 3 and 5 (Dynabeads CD31 Endothelial Cell; Thermo Fisher Scientific). Before confluency, cells were harvested by trypsin digestion and subsequently cryopreserved. Before testing, endothelial cells were grown in EGM-2-MV medium to 80% confluency until they were harvested with 10 mmol/L EDTA for 2 h at 37°C. For selected experiments, cells were incubated for 14 h with a cytokine cocktail consisting of interleukin (IL)-1b (5 ng/mL), tumor necrosis factor (TNF)a (1000 units/mL), and interferon (IFN)c (300 units/mL) to enhance or induce the expression of HLA on the endothelial cell surface (28, 29) . First, 5 9 10 4 cells were incubated with allosera (75% of the incubation solution volume) in the presence or absence of anti-C1s antibodies for 30 min at 22°C. C3 split product deposition or IgG binding was then detected at 4°C by using biotinylated anti-human C3d antibody (Quidel, 4 lg/mL) followed by PE-coupled streptavidin (1 lg/mL) or PE-labeled anti-human IgG (One Lambda, Inc.; final dilution 1:100) antibody, respectively. Endothelial cells were gated according to staining with allophycocyanin (APC)-coupled anti-CD31 (eBioscience; final dilution: 2 lg/mL).
Splenic lymphocytes were isolated by mechanical dissociation and sieving through a Falcon 70-lm Cell Strainer (Corning Inc., Corning, NY) followed by density gradient centrifugation. Cells were then washed with RPMI 1640 and frozen in liquid nitrogen until testing. For antibody and complement detection, 1.25 9 10 5 cells were incubated with serum with or without complement inhibition, followed by the detection of C3b/d or IgG as described for AECs. In addition, cells were stained with APC-coupled CD3 and CD19 antibodies (eBioscience). Measurements were performed on a FACSCanto II cytometer (BD Biosciences, San Jose, CA).
Statistical evaluation
Half-maximal inhibitory concentration (IC 50 ) values were computed by using a 4p logistic curve fit. For statistical comparisons, we used MannWhitney U or Wilcoxon signed-rank tests as appropriate. For correlation statistics, Spearman rank test was used. Statistical analysis was performed by using SPSS (version 20.0.0; IBM Corp., Armonk, NY) and GraphPad Prism (version 6.01; GraphPad Software Inc., La Jolla, CA).
Results
Binding of TNT009 and TNT003 to HLA antibodybound C1s First, we evaluated the ability of the humanized anti-C1s mAb TNT009 (IgG4) and its mouse variant TNT003 (IgG2a) to bind C1s on SAFBs incubated with polyspecific alloserum. As shown in Figure 1 , the amount of C1s attached to the surface of individual beads was correlated to the amount of IgG binding, showing maximum antibody binding at concentrations >20 lg/mL ( Figure 1 ).
Effect of anti-C1s mAbs on the attachment of C1 complex components to SAFBs Next, we investigated the effect of TNT009 and TNT003 on levels of C1q, C1r, and C1s staining. As illustrated in Figure 2 , TNT003 led to a significant increase in C1s MFI. A similar effect was observed for C1r ( Figure S2 ). In addition, there was a numerical increase in median C1q MFI, but differences did not reach statistical significance (Figure 2 ). This effect was in part related to inhibition of subsequent CP activation steps (C3b/d deposition) known to sterically interfere with the proper detection of IgG and C1 components (26, 30 
Effect of anti-C1s mAbs on HLA antibody-triggered C3 activation
In all subsequent experiments, we focused on C3 split product deposition, which reflects C3 activation, the central node of the entire complement system. Anti-C1s mAbs profoundly inhibited C3 split product deposition, showing a steep concentration-effect relationship between 20 and 62.5 lg/mL ( Figure 3 ). Maximum inhibition of C3b/d deposition was achieved at concentrations >20 lg/mL. TNT009 or TNT003 at 250 lg/mL reduced median C3b/d MFI from 5643 (IQR: 1381-6634; 47 C3b/ d-fixing SAFB) to 161 (IQR: 23-2179) or 101 , respectively. As shown in Figure 3 , the IC 50 values fell into a range between 10 and 100 lg/mL. IC 50 was related to individual baseline levels of C3b/d deposition, and for a subset of SAFB showing extensive levels of complement deposition (≥5000 C3b/d MFI), values >100 lg/mL were computed ( Figure 3 ).
Effect of TNT009 on CP activation in cellular assays
To evaluate the effect of TNT009 on HLA antibodytriggered CP activation in cellular assays, human AECs Efficacy of TNT009 in sensitized kidney transplant candidates with varying levels of CP activating HLA reactivity Finally, we investigated the in vitro effect of TNT009 on HLA antibody-triggered C3 activation in a large sample of HLA-sensitized individuals. Figure 6 illustrates the CP inhibition by TNT009 and isotype control at 250 lg/mL in relation to baseline levels of C3b/d deposition (serum alone) on HLA class I (a total of 4365 single reactivities recorded for 45 subjects) and HLA class II SAFB (5130 single reactivities; 54 subjects). While a nonspecific isotype control did not affect C3b/d MFI levels, TNT009 . For a separate analysis of single bead reactions with >4000 baseline C3d MFI, we defined resistance to TNT009 treatment as a ≤90% reduction in C3d MFI (in relation to serum treatment with nonspecific IgG4) and found that "treatment-resistant" single bead reactions were associated with significantly higher baseline levels of IgG and C3d binding than those showing >90% inhibition. In addition, single bead reactions on HLA-A and -DQ antigencoated beads were more often "resistant" to CP blockade, while the opposite was true for HLA-B and HLA-DR (Table S1 ). Beads coated with different HLA antigens, however, did not differ with respect to levels of IgG binding or C3d deposition (data not shown).
Discussion
In this study, we investigated the mode of action and the efficacy of the humanized anti-C1s mAb TNT009, a specific CP inhibitor currently in clinical trials for the treatment of complement-mediated diseases (23) . This antibody and its parental mouse variant TNT003 were tested for their ability to prevent HLA antibody-triggered CP activation using solid phase and cell-based test systems. A major finding was a virtually complete blockade of activation of the key complement components C4 and C3. Anti-C1s mAbs colocalized with IgG-associated C1s but did not decrease the deposition of C1 subcomponents to the site of bound alloantibodies, leading to the interpretation that TNT009 and TNT003 do not prevent the C1 complex from binding to IgG but rather prevent the cleavage of C4 by C1s.
Our experimental approach of analyzing sequential steps of CP activation on artificial and cellular surfaces may provide a useful platform for dissecting the effects of novel complement inhibitors on HLA antibody-triggered CP activation. Our finding of profound and specific in vitro blockade of the classic complement cascade by humanized mAb TNT009 provides a foundation for its further evaluation in clinical transplantation. Indeed, in recent years, the concept of complement inhibition as a strategy to counteract AMR has gained increasing interest, and the first human trials evaluating complement inhibitors, such as C1-INH or eculizumab (11, 13, (17) (18) (19) 31) , have provided some evidence for clinical efficacy. One may speculate that the CP-specific mode of action of TNT009 could be beneficial in terms of preserved immunity, because it leaves other complement pathways, such as the lectin pathway, intact. However, considering the recently proposed role of the lectin pathway as a trigger of rejection (32) and ischemia-reperfusion injury (33) , one may also argue that this could limit efficiency in counteracting tissue injury. Currently, the specific approach of targeting the CP at the level of C1s is being evaluated in a phase 1 trial primarily designed to assess not only safety and tolerability of TNT009 but also efficacy in various CP-mediated disorders. This trial was designed to enroll both healthy volunteers and patients including kidney transplant recipients with late AMR (ClinicalTrials.gov Identifier: NCT02502903) (23).
Considering their identical Fab region, it was not surprising that TNT009 and TNT003 showed similar pharmacological properties, as demonstrated in dilution experiments. Antibody binding studies using immunofluorescent staining revealed somewhat higher MFI values for TNT003 compared with TNT009. This, however, may not necessarily reflect a higher affinity of the mouse variant, as differences may have been due to the use of different detection reagents and staining techniques (indirect vs. direct staining). The only remarkable difference was an apparent attraction of C1 subcomponents to the solid phase by TNT003. We initially speculated that this increase was a result of CP inhibition and thus blockade of the in vitro artifact of complement-dependent interference (frequently termed "prozone effect") (34) . Earlier studies have shown that CP activation products, in particular the surface binding of C4 and C3 split products C4b/d or C3b/d, interfere with the detection of upstream events including IgG binding or C1 attachment (26, 30) . Consistent with these studies, the results presented here demonstrate that serum pretreatment with the complement inhibitors MeNH 2 (for C4 and C3 inhibition) or CVF (for selective C3 inhibition) led to increased detection of early complement products. However, further inhibition experiments revealed that complementdependent interference was only partly responsible for the detected increase in C1 levels, suggesting a major contribution of additional C1 attraction by the wellestablished complement-fixing capability of the isotype (IgG2a) of TNT003 (35) . This interpretation of our results is supported by the fact that TNT009, which is a noncomplement-activating human IgG4, did not increase C1 subcomponent deposition.
Analyzing the impact on C3, specifically C3 split product deposition, which may be less prone to misleading in vitro artifacts, we demonstrated similar efficacy between TNT009 and its parental variant TNT003. Both antibodies exerted excellent control over complement activation at concentrations >20 lg/mL, in solid phase and cellular assays. Notably, in two previous studies, one focusing on the inhibitory effect of TNT003 in an in vitro model of cold agglutinin-mediated hemolysis (21) 
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complement activation was observed at lower concentrations. In these earlier studies, a higher dilution of test sera, and thus a lower concentration of available C1s protease, was used (ranging from 25% to 37.5% vs. 75% in the present study), which may explain differences in TNT003 potency.
Analyzing patterns of complement inhibition on individual SAFBs, we found a dependency of IC 50 values on the baseline levels of complement deposition. Interestingly, IC 50 values did not associate with levels of C3d deposition, when the latter was increased on upregulation of HLA expression in cellular assays. We have no definitive explanation for this differential behavior. We assume that differences are due to variable complement binding and activating properties of individual alloantibodies detected in SAFB assays (36) or to differences between artificial beads and cells regarding the mode of antigenic expression (e.g. physiological capping/clustering behavior of HLA molecules on fluidic cell membranes) (37). TNT009 also efficiently inhibited the CP in cellular models of HLA antibody-triggered complement activation, which may better mirror the clinical situation of AMR. Reed and coworkers (22) found 2.5-fold higher IC 50 values for TNT003 on beads compared with human AECs, and they ascribed this difference to higher levels of available C1s in the solid phase assays (37.5% vs. 25% in cellular assays) or, alternatively, to a lack of complement inhibitory receptors on bead surfaces. Our failure to detect meaningful differences in potency in head-to-head comparisons between assay systems when using a constant dilution of defined monospecific or polyspecific allosera (75 vol%) supports the belief that C1s levels are the primary determinant of TNT003 potency.
One interesting observation was the inability of TNT009 to completely inhibit complement deposition on B cells induced by an alloserum containing monospecific complement-fixing reactivity (HLA-A2). In contrast, HLA-A2-expressing T cells and AECs incubated in the same alloserum showed complete inhibition of C3 deposition by TNT009. B cells, unlike T cells and AECs, contain complement receptor 2 on their membranes. Therefore, one possible explanation is that this particular serum contains significant levels of preformed soluble C3 split products, which may be binding to complement receptor 2 on the B cell surface (38, 39) .
To assess the CP inhibitory potential of TNT009 in a representative patient sample, the antibody was tested in a large number of defined HLA class I-and/or class IIreactive allosera, some of them containing extensive levels of C3-activating alloreactivity. We found that, at the highest concentration tested in vitro (250 lg/mL), TNT009 consistently blocked C3 activation in samples inducing baseline C3b/d MFI levels up to 4000. However, at higher baseline values, extensive complement activation gradually overwhelmed inhibition. Apart from a role of IgG binding strength and the extent of baseline CP activation, we found that single reactions on HLA-A and -DQ antigen-coated beads were less often responsive to CP blockade, while the opposite was true for HLA-B and -DR reactions. Our experiments cannot provide a definite explanation for these differences, but one may speculate a possible role of HLA antigen-specific differences in IgG subclass distribution, binding densities of HLA molecules on artificial bead surfaces and/or a contribution of other complement-activating immunoglobulin classes, such as IgM. A phase 1 trial designed to determine the optimal working range concentration of this novel therapeutic antibody is currently under way and will address the dose and dose regimen required to maintain sustained inhibition of the classic pathway.
The results of this study demonstrate that TNT009 and its parental mouse variant TNT003 potently inhibit HLA antibody-mediated CP activation. Our study provides a foundation for future trials evaluating the clinical benefit of this novel complement inhibitor in the setting of organ transplantation.
Disclosure Supporting Information
Additional Supporting Information may be found in the online version of this article. Figure S1 : Blockade of HLA antibody-triggered classical pathway activation by interference with antiC1s antibodies TNT009 and TNT003, methylamine, and cobra venom factor. Antigenic binding of anti-HLA antibody leads to Fc binding and assembly of C1 complex (C1qr2s2). The enzymatic C1s subunit, the target of anti-C1s antibodies TNT009 and TNT003, cleaves C4 and C2. C4 is cleaved to C4a and C4b, which, via its internal thioester, covalently binds to the site of complement activation forming the classic pathway (CP) C3 convertase (C4bC2a). The latter triggers subsequent activation steps by cleaving C3 to C3a and C3b. C3b covalently binds to the surface and together with C4bC2a forms the CP C5 convertase, which cleaves C5 to C5a and C5b, a critical step toward terminal complex formation. Inactivation of C4b and C3b by complement regulatory proteins leads to the formation of covalently bound C4d and C3d split products. Methylamine inactivates the internal thioester, preventing the covalent binding of C4b and C3b to the bead surface. Treatment with cobra venom factor results in the cleavage and consumption of C3 (some forms of cobra venom factor also target C5). beads (SAFBs) that stained positive with methylamine (MeNH 2 )-or cobra venom factor (CVF)-treated serum (MFI threshold for both complement products >100), respectively. Assays were performed using either untreated alloserum or serum preincubated with MeNH 2 or CVF to prevent complement-dependent interference. PBS or nonbinding IgG2a and IgG4 were used as the corresponding negative controls. (C) To assess the impact of CVF on C3b/ d deposition, SAFBs were stained for C3 split product deposition in the presence or absence of CVF, whereby 41
SAFBs that stained positive with PBS-treated serum (MFI >100) were included in the analysis. Box plots indicate median and IQR (outliers: circles, extreme outliers: asterisks). For statistical comparisons the Mann-Whitney U was used. 
